Comparing the current results to its competitors, Equillium Inc reported Revenue decrease in the 1 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 1.55 %, recorded in the same quarter.
Equillium Inc 's Comment on Competition and Industry Peers
The company competes with major pharmaceutical and biotechnology firms, academic institutions, governmental agencies, and public and private research organizations. Its product candidates face competition from existing and future therapies. Key competitive factors include efficacy, safety, convenience, generic competition, and reimbursement availability. Competitors may also achieve regulatory approvals more quickly, potentially securing strong market positions prior to the company's market entry.
June 12, 2024
LA JOLLA, CA Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company recognized for its innovative approach to developing therapeutics targeting severe autoimmune and inflammatory disorders, proudly announced that it expects to be included in the Russell Microcap Index. This anticipated inclusion is part of the 2024 Russell annual reconstitution process. The official addition will take effect when the equity markets open on Monday, July 1, as per the preliminary list of additions released on Friday, May 24. Significance of Russell Microcap Index Inclusion The Russell Microcap Index is a widely respected benchmark, encompassing the smallest 1,000 companies in the Russell 2000, along with the n...
Macrogenics Inc is a biopharmaceutical company that focuses on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer and autoimmune diseases.
Kezar Life Sciences Inc is a biotechnology company that focuses on developing novel small molecule therapeutics. Their business model revolves around the discovery and development of innovative drugs to target autoimmune and inflammatory disorders, aiming to address unmet medical needs. They primarily operate by conducting extensive research and conducting clinical trials to deliver effective treatments for patients.
Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.
Immunic Inc is a biotechnology company that focuses on developing and commercializing small molecule therapies for immune-related diseases. Their business model involves conducting research, clinical trials, and obtaining regulatory approvals, followed by marketing their products to healthcare providers and patients globally.
Sources:
Equillium Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Equillium Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
